Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.
Evotec will gain non-exclusive rights to Ncardia IP, including a broad panel of stem cell-derived cell lines for use in drug target discovery and testing.
The companies will offer CDI's human induced pluripotent stem cell-derived tissue cells with Nanion's ion channel drug discovery and screening platform.
Eleven new studies from the NHLBI NextGen Consortium show different uses for iPSCs to study polygenetic diseases across various systems in the human body.
The deal gives Axiogenesis access to IP that will allow it to commercialize stem cell-derived assays and disease models for use in drug discovery.
NEW YORK (GenomeWeb News) – Cambridge, UK-based Definigen said today that it has raised a total of £2.3 million ($3.8 million) in a Series A round of funding.
Epistem plans to use novel preclinical models for cutaneous wound healing developed by a University of Manchester scientist under a partnership that is supported by a UK government business development program.
ILS and Stemina Biomarker Discovery today announced they will work together to advance Stemina's stem cell-based toxicology testing platform.
CIT will distribute Stemina's devTOX assay in Europe, and the two companies will develop other technologies to assess the safety of compounds for animal and human use.
At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.
The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.
Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.
In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.